Sales and profits at GSK (LSE: GSK) beat expectations in the second quarter of 2023, with the firm reporting respectively a 4% and 8% increase from the same period of last year.
Britain’s second-largest drugmaker took in £7.2 billion ($9.2 billion) sales for the period, with £2.2 billion in profit, leading to an adjusted earnings per share (EPS) result of £0.38.
Headquartered in West London, GSK has a broad range of products, with particular expertise in vaccines, respiratory conditions and medicines for HIV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze